Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Kalkine 0
countryflagAU

Medical Developments International

Healthcare AU MVP

0.62AUD
-(-%)

Last update at 2025-06-06T06:11:00Z

Day Range

0.590.63
LowHigh

52 Week Range

0.380.94
LowHigh

Fundamentals

  • Previous Close 0.62
  • Market Cap69.85M
  • Volume258034
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA0.23M
  • Revenue TTM38.05M
  • Revenue Per Share TTM0.39
  • Gross Profit TTM 28.08M
  • Diluted EPS TTM-0.34

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -7.49200M -15.90800M -14.97800M 0.32M 1.55M
Minority interest - - - - -
Net income -5.60900M -12.40700M -12.56500M 0.38M 1.04M
Selling general administrative 32.58M 22.21M 15.23M 5.59M 5.40M
Selling and marketing expenses 3.83M 2.60M 4.75M 5.38M 4.27M
Gross profit 22.04M 15.63M 19.10M 14.99M 14.18M
Reconciled depreciation 3.11M 2.94M 3.75M 2.60M 2.27M
Ebit -0.68800M -15.22400M -6.01300M 0.43M 1.62M
Ebitda 2.42M -10.68500M -2.26400M 3.03M 3.89M
Depreciation and amortization 3.11M 4.54M 3.75M 2.60M 2.27M
Non operating income net other - - - - -
Operating income -17.30400M -12.54500M -3.47400M 2.44M 1.62M
Other operating expenses -20.14100M -24.74900M -30.66800M -7.34500M 21.97M
Interest expense 0.10M 0.10M 0.00900M 0.11M 0.07M
Tax provision -1.88300M -3.50100M -2.41300M -0.05800M 0.51M
Interest income 0.66M 0.04M 0.07M 0.34M 0.45M
Net interest income 0.56M -0.05800M -0.05000M -0.11400M 0.38M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -1.88300M -3.50100M -2.41300M -0.05800M 0.51M
Total revenue 32.17M 22.37M 25.27M 22.54M 20.88M
Total operating expenses 42.48M 32.50M 28.82M 17.49M 15.28M
Cost of revenue 10.12M 6.74M 6.17M 7.54M 6.69M
Total other income expense net 12.39M -0.58100M -8.95600M -2.12000M -0.07100M
Discontinued operations - - - - -
Net income from continuing ops -5.60900M -12.40700M -12.56500M 0.38M 1.04M
Net income applicable to common shares -5.60900M -12.40700M -12.56500M 0.38M 1.04M
Preferred stock and other adjustments - - - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 63.77M 101.31M 92.22M 100.17M 84.76M
Intangible assets - 34.51M 36.88M 34.46M 35.82M
Earning assets - - - - -
Other current assets 0.56M 0.79M 0.78M 2.73M 0.45M
Total liab 18.04M 20.00M 34.92M 31.87M 41.42M
Total stockholder equity 45.73M 81.31M 57.30M 68.30M 43.34M
Deferred long term liab - 32.70M 35.12M 32.81M 33.87M
Other current liab 0.64M 1.59M 4.88M 3.25M 1.56M
Common stock 105.73M 105.73M 76.99M 76.89M 40.95M
Capital stock - 105.73M 76.99M 76.89M 40.95M
Retained earnings -62.85900M -30.15400M -24.54500M -12.13800M 0.43M
Other liab - 2.24M 21.98M 22.20M 30.27M
Good will 3.81M 3.81M 3.81M 4.39M 9.10M
Other assets 0.00000M 8.11M 40.74M 35.05M 35.98M
Cash 9.73M 24.66M 20.40M 36.28M 15.54M
Cash and equivalents - 24.66M 20.40M 36.28M 15.54M
Total current liabilities 9.55M 15.55M 10.48M 6.96M 8.21M
Current deferred revenue 0.28M 0.28M 0.08M 0.07M 2.39M
Net debt -7.44900M -22.10100M -17.58500M -33.22800M -12.18800M
Short term debt 0.37M 0.35M 0.35M 0.34M 0.42M
Short long term debt - - - - 0.09M
Short long term debt total 2.29M 2.56M 2.81M 3.05M 3.36M
Other stockholder equity - -75.57500M -52.44700M -64.75700M -41.38100M
Property plant equipment - 12.12M 11.55M 11.70M 11.78M
Total current assets 26.14M 42.76M 34.37M 47.39M 25.96M
Long term investments - - - - -
Net tangible assets - 75.70M 51.74M 62.27M 32.29M
Short term investments - - - - -
Net receivables 7.07M 8.93M 6.08M 2.65M 4.08M
Long term debt - - - 0.00000M 0.00000M
Inventory 8.77M 8.38M 7.11M 5.73M 5.88M
Accounts payable 8.25M 13.32M 5.17M 3.30M 3.84M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 2.86M 5.74M 4.85M 3.54M 1.96M
Additional paid in capital - - - - -
Common stock total equity - - - - 40.95M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 16.04M -17.73800M -17.11400M 0.00100M -22.73900M
Deferred long term asset charges - - - - -
Non current assets total 37.63M 58.55M 57.85M 52.79M 58.80M
Capital lease obligations - 2.56M 2.81M 3.05M 3.27M
Long term debt total - 2.21M 2.46M 2.71M 2.94M
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Investments -3.16900M -7.09900M -5.15900M -6.47800M -8.47200M
Change to liabilities - 2.36M 0.90M 1.02M 1.97M
Total cashflows from investing activities - -7.09900M -5.15900M -6.47800M -8.47200M
Net borrowings - -0.25300M -0.21500M -0.23200M -0.28800M
Total cash from financing activities -0.80700M 28.06M 0.14M 36.12M -1.96600M
Change to operating activities - -0.15400M -0.01900M -10.22300M -1.65600M
Net income -40.99200M -5.60900M -12.40700M -12.56500M 0.38M
Change in cash -14.92600M 4.26M -15.87900M 20.73M -10.07600M
Begin period cash flow 24.66M 20.40M 36.28M 15.54M 25.62M
End period cash flow 9.73M 24.66M 20.40M 36.28M 15.54M
Total cash from operating activities -10.78000M -16.49500M -10.72200M -8.80800M 0.17M
Issuance of capital stock - 30.00M 0.36M 37.07M 0.40M
Depreciation 3.39M 3.11M 2.94M 3.75M 1.53M
Other cashflows from investing activities -2.37600M -5.31500M -3.96000M -5.23100M 0.43M
Dividends paid - 26.38M 0.14M 35.53M 2.06M
Change to inventory -0.39300M -1.84200M -1.37400M 0.15M -2.83300M
Change to account receivables 1.86M -2.87000M -2.50000M 1.43M 2.30M
Sale purchase of stock -0.53300M -1.68400M -0.00300M -0.72700M -0.01300M
Other cashflows from financing activities -0.27400M -0.25300M -0.21500M -0.14100M -0.19700M
Change to netincome - -12.06100M 1.68M 7.54M -2.59100M
Capital expenditures 3.17M 7.67M 5.21M 6.56M 8.90M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 4.18M -2.50400M -3.59000M -9.92000M -0.53100M
Stock based compensation - 1.26M 1.03M 1.17M 0.09M
Other non cash items 22.64M -5.38100M 9.75M 8.89M -1.73500M
Free cash flow -13.94900M -24.16000M -15.93600M -15.36800M -8.72900M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
MVP
Medical Developments International		 - -% 0.62 - 166.67 1.84 1.25 1.41 278.77
AFP
AFT Pharmaceuticals Ltd		 0.10 4.00% 2.60 25.00 21.55 1.32 2.89 1.53 14.62
VLS
Vita Life Sciences Ltd		 0.08 4.17% 2.00 12.00 - 1.33 2.02 0.98 5.78
SNT
Syntara Limited		 0.004 6.15% 0.07 - 20.45 12.95 5.62 6.32 -2.1607
VIT
Vitura Health Limited		 0.001 1.47% 0.07 - - 0.36 1.10 0.44 9.76

Reports Covered

Stock Research & News

View All

Profile

Medical Developments International Limited manufactures and distributes emergency medical solutions in Australia, Europe, the United States, and internationally. The company operates through Pain Management and Respiratory segments. It offers Penthrox, a trauma and emergency pain relief product for use in hospitals, emergency departments, ambulance services, sport medicines, and for analgesia during short procedures. The company also distributes asthma and chronic obstructive pulmonary disease products, such space chambers, peak flow meters, portable nebulisers, and silicon face mask. The company was founded in 1972 and is headquartered in Scoresby, Australia.

Medical Developments International

4 Caribbean Drive, Scoresby, VIC, Australia, 3179

Key Executives

Name Title Year Born
Mr. Brent MacGregor Chief Exec. Officer 1964
Ms. Anita James Chief Financial Officer NA
Matthew Cramer Chief of Operations & Supply Chain NA
Ms. Tara Eaton Gen. Counsel & Company Sec. NA
Ms. Greer Lucas Head of People & Culture NA
Dr. Scott Courtney Chief Scientific Officer NA
Wai Ng Chi Head of Regulatory Affairs NA
Wayne Pearce Head of Production NA
Mr. Stefaan Schatteman Head of Europe NA
Mr. Brent MacGregor Chief Executive Officer 1964

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.